首页> 外文OA文献 >P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

【2h】

P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

机译：P590在持续的，非介入性，观察患者的临时分析现实世界安全数据的临时分析，观察患者用CT-P13处理的炎症性肠病患者，incriximab生物酸蛋白，在通常护理的范围内与参考英夫利昔单抗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
B Bokemeyer; T Hlavaty; M Allez; P Selema; S Moosavi; M J Cadatal; H Fowler; R Cheung; M Lukas; J P Gisbert;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease [J] . María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, World Journal of Gastroenterology . 2018,第46期

机译：在炎症性肠病患者中从原来的英夫利昔单抗改用英夫利昔单抗生物仿制药（CT-P13）的疗效和安全性丧失
2. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [J] . Yoo Dae Hyun, Prodanovic Nenad, Jaworski Janusz, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第2期

机译：CT-P13（BioSimilarIngiximab）在类风湿性关节炎患者中的功效和安全性：从Planetra延伸研究中的CT-P13切换到CT-P13的切换与Planetra延伸研究中的持续CT-P13的比较
3. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease [J] . Ebada Mahmoud Ahmed, Elmatboly Abdelmagid M., Ali Ahmed Said, International journal of colorectal disease. . 2019,第10期

机译：关于英夫利昔单抗生物蛋白酶CT-P13的安全性和疗效的更新系统审查和荟萃分析，炎症性肠病患者
4. Analysis of Microbiome Data across Inflammatory Bowel Disease Patients [C] . Wisittipanit Nuttachat, Rangwala Huzefa, Gillevet Patrick Machine Learning and Applications and Workshops (ICMLA), 2011 10th International Conference on . 2011

机译：炎症性肠病患者的微生物组数据分析
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter observational study in Italian primary inflammatory bowel disease centers [O] . Antonio Tursi, Giammarco Mocci, Roberto Faggiani, 2019

机译：英夫利昔单抗生物仿制药CT-P13在治疗炎症性肠病方面是有效和安全的：在意大利原发性炎症性肠病中心进行的现实多中心观察性研究
7. FRI0122 REAL-WORLD SAFETY DATA FROM PATIENTS WITH RHEUMATIC DISEASES TREATED WITH CT-P13, AN INFLIXIMAB BIOSIMILAR: AN INTERIM ANALYSIS FROM AN OBSERVATIONAL STUDY [O] . Peter C. Taylor, Robin Christensen, Shahrzad Moosavi, 2019

机译：从CT-P13处理的风湿病患者的Fri0122现实安全数据，incriximab生物酸钠：从观察研究中的临时分析

P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

著录项

引文网络

相似文献

相关主题

期刊订阅